# Odyssey Therapeutics, Inc.: financial statements, quarterly

ODTX · Nasdaq · CIK 1882782 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/odtx.md) · [Financials](/companies/odtx/financials.md) · [Filings](/companies/odtx/filings.md) · [Insiders](/companies/odtx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/odtx/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.9](/filings/0001193125-26-274290.md) | [1.0](/filings/0001193125-26-335822.md) | [0.0](/filings/0001193125-26-274290.md) | [0.0](/filings/0001193125-26-335822.md) |
| Research and development | $m | [38.8](/filings/0001193125-26-274290.md) | [30.2](/filings/0001193125-26-335822.md) | [32.3](/filings/0001193125-26-274290.md) | [36.2](/filings/0001193125-26-335822.md) |
| Operating income | $m | [(39.2)](/filings/0001193125-26-274290.md) | [(41.9)](/filings/0001193125-26-335822.md) | [(39.8)](/filings/0001193125-26-274290.md) | [(55.5)](/filings/0001193125-26-335822.md) |
| Interest expense | $m | [0.0](/filings/0001193125-26-274290.md) | [0.0](/filings/0001193125-26-335822.md) | [0.0](/filings/0001193125-26-274290.md) | [0.0](/filings/0001193125-26-335822.md) |
| Income tax | $m | [0.1](/filings/0001193125-26-274290.md) | [0.0](/filings/0001193125-26-335822.md) | [0.1](/filings/0001193125-26-274290.md) | [(0.0)](/filings/0001193125-26-335822.md) |
| Net income | $m | [(38.4)](/filings/0001193125-26-335822.md) | [(41.2)](/filings/0001193125-26-335822.md) | [(38.3)](/filings/0001193125-26-335822.md) | [(52.8)](/filings/0001193125-26-335822.md) |
| Diluted EPS | $ per share | [(39.37)](/filings/0001193125-26-274290.md) | [(29.54)](/filings/0001193125-26-335822.md) | [(6.77)](/filings/0001193125-26-274290.md) | [(1.74)](/filings/0001193125-26-335822.md) |
| Basic EPS | $ per share | [(39.37)](/filings/0001193125-26-274290.md) | [(29.54)](/filings/0001193125-26-335822.md) | [(6.77)](/filings/0001193125-26-274290.md) | [(1.74)](/filings/0001193125-26-335822.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [54.9](/filings/0001193125-26-274290.md) | [163](/filings/0001193125-26-335822.md) | [41.7](/filings/0001193125-26-335822.md) | [35.7](/filings/0001193125-26-274290.md) | [82.0](/filings/0001193125-26-335822.md) |
| Current assets | $m | not reported | not reported | not reported | [191](/filings/0001193125-26-335822.md) | [185](/filings/0001193125-26-274290.md) | [321](/filings/0001193125-26-335822.md) |
| Total assets | $m | not reported | not reported | not reported | [270](/filings/0001193125-26-335822.md) | [229](/filings/0001193125-26-274290.md) | [484](/filings/0001193125-26-335822.md) |
| Current liabilities | $m | not reported | not reported | not reported | [26.5](/filings/0001193125-26-335822.md) | [22.2](/filings/0001193125-26-274290.md) | [28.3](/filings/0001193125-26-335822.md) |
| Total liabilities | $m | not reported | not reported | not reported | [54.5](/filings/0001193125-26-335822.md) | [49.2](/filings/0001193125-26-274290.md) | [62.6](/filings/0001193125-26-335822.md) |
| Shareholders' equity | $m | [(383)](/filings/0001193125-26-335822.md) | [(417)](/filings/0001193125-26-335822.md) | [(436)](/filings/0001193125-26-335822.md) | [(488)](/filings/0001193125-26-335822.md) | [(524)](/filings/0001193125-26-335822.md) | [421](/filings/0001193125-26-335822.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(38.6)](/filings/0001193125-26-274290.md) | [(34.3) d](/filings/0001193125-26-335822.md) | [(41.0)](/filings/0001193125-26-274290.md) | [(34.5) d](/filings/0001193125-26-335822.md) |
| Capital expenditure | $m | [0.9](/filings/0001193125-26-274290.md) | [0.0 d](/filings/0001193125-26-335822.md) | [0.1](/filings/0001193125-26-274290.md) | [0.2 d](/filings/0001193125-26-335822.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.0](/filings/0001193125-26-274290.md) | [1.4](/filings/0001193125-26-335822.md) | [5.7](/filings/0001193125-26-274290.md) | [30.3](/filings/0001193125-26-335822.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 48,058,527 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-335822.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.